Jacinto Convit World Organization, Inc.
Our mission is to give access to better healthcare solutions to those who need it the most, while training the new generations
Programs and results
What we aim to solve
For many people around the world, having access to molecular techniques used in diagnosis or control of diseases is as simple as any other basic blood test. However, this is not the case for most developing countries. Therefore we support the expansion of the Molecular Diagnostic Unit run by partner organizations in South America, within our Molecular Diagnostics program. In low-income countries, many patients do not have access to new innovative therapies and in some cases, to standard of care treatments. To bring to them effective and accessible immunotherapies will make an impact in these patients life and improve the local health care system.
Our programs
What are the organization's current programs, how do they measure success, and who do the programs serve?
Molecular Diagnostics
Considering the improved survival rates for childhood cancer when an early and precise diagnose is performed, JCWO builds international support for the Molecular Diagnostic Unit; a pioneer program that consists of a personalized, precise, and free of cost diagnostic service for pediatric cancers and endemic infectious diseases for underprivileged children that are treated in public hospitals in South America.
Cancer Immunotherapy
This program seeks to make Dr. Convit’s breast cancer immunotherapy a standard low cost treatment option for patients. Through partnerships with research and health centers, JCWO works to advance its clinical trials in the US, South America and Europe using the ConvitVax. Additionally, this program looks to further enhance the anti-tumor effect of the ConvitVax by testing it in combination with other breast cancer therapies, as well as evaluate it as a treatment for other types of malignant solid tumors. With this program we direct our efforts to develop accessible immunotherapy protocols that can be affordable for underprivileged patients who lack the possibility of entering new innovative treatments.
Where we work
External reviews
Our results
How does this organization measure their results? It's a hard question but an important one.
Number of overall donors
This metric is no longer tracked.Totals By Year
Type of Metric
Other - describing something else
Direction of Success
Increasing
Number of attorney volunteers
This metric is no longer tracked.Totals By Year
Type of Metric
Input - describing resources we use
Direction of Success
Holding steady
Context Notes
Since our inception, we receive the support of two important law firms.
Number of research studies conducted
This metric is no longer tracked.Totals By Year
Related Program
Cancer Immunotherapy
Type of Metric
Output - describing our activities and reach
Direction of Success
Holding steady
Number of adults satisfied with the health care system in the community
This metric is no longer tracked.Totals By Year
Population(s) Served
Adults, Children and youth
Related Program
Molecular Diagnostics
Type of Metric
Output - describing our activities and reach
Direction of Success
Increasing
Context Notes
To date, 7,230 diagnoses have been made, benefiting 1,446 patients and 5,784 relatives and patient representatives.
Number of children who have access to healthcare
This metric is no longer tracked.Totals By Year
Population(s) Served
Children and youth
Related Program
Molecular Diagnostics
Type of Metric
Output - describing our activities and reach
Direction of Success
Increasing
Number of new organizations signing on as collaborators
This metric is no longer tracked.Totals By Year
Type of Metric
Other - describing something else
Direction of Success
Increasing
Context Notes
Organizations or individual persons as collaborators
Number of Facebook followers
This metric is no longer tracked.Totals By Year
Type of Metric
Other - describing something else
Direction of Success
Increasing
Context Notes
Additionally, there are 560 followers on Linkedin, 305 on Twitter and 458 on Instagram.
Our Sustainable Development Goals
Learn more about Sustainable Development Goals.
Goals & Strategy
Learn about the organization's key goals, strategies, capabilities, and progress.
Charting impact
Four powerful questions that require reflection about what really matters - results.
What is the organization aiming to accomplish?
Our current efforts are centered on two main programs, Molecular Diagnostics and Cancer Immunotherapy.
The Molecular Diagnostics program is based on supporting the expansion of the Molecular Diagnostic Unit in South America. It consists on a personalized, precise, and free of cost diagnostic service for cancers and endemic infectious diseases for underprivileged patients (mainly children) that are treated in public hospitals of the region.
The Cancer Immunotherapy program seeks to make Dr. Convit’s cancer immunotherapy a standard low cost treatment option for cancer patients. Through partnerships with research and health centers, JCWO works to advance in the execution of clinical trials in South America, the U.S. and Europe, using the ConvitVax as a treatment for breast cancer and other solid tumors. This immunotherapy is specially targeted to poor countries where there is very little or no access to new cancer treatments and in some cases to standard of care treatments.
Our goals and activities for this year are:
Project development
Alliances
Fundraising
Dissemination
Human Resources
What are the organization's key strategies for making this happen?
We want to development theses sttategies:
Establish with AJVaccine the necessary documentation for the shipment of BCG and PPD.
Finalize the clinical protocol with the specialists.
Adjust the format and send clinical protocol to FDA.
Establish allies in the USA and Spain for the execution of the clinical trial.
Support the development of the new combination pre-clinical protocol.
Support in data processing and writing of the manuscript.
Organize and write the Leishmaniasis project
Review of WHO requirements and application for approval.
Find interested institutions in the leishmaniasis vaccine and sign an agreement or submit application
Create a database of countries and centers for the diagnosis of solid tumors.
Prepare the solid tumors project for the diagnostic service.
Send the project to interested centers in tumor solid diagnostics and sign an agreement.
Find new cooperative institutions with whom JCWO can partner to performing a clinical trial inside and outside the US.
Hold meetings where JCWO can present the clinical trial and establish alliances for its different projects
Arrange the material and send partnership requests to the institutions listed in the data base, and keep contact with those that agree to participate in the clinical trial.
Sign collaboration agreements with hospitals for clinical trial execution.
Find organizations that want to collaborate in the scientific and educational programs of JCWO.
Send letters and set up meetings with the necessary requests for the programs.
Follow up and establish agreements with the organizations contacted that can support JCWO
Arrange agreements with institutions or universities that can support the JCWO programs.
Continue to expand the database of organizations and institutions for the application of financing.
Submit grant applications for the scientific programs in which JCWO can qualify.
Create new strategies for the search and raising of funds (campaigns, meetings, among others)
Generate a database of companies with social corporate responsibility to request funds.
Contact through calls and letters for the presentation of programs and request for financing to individuals and companies
Establish strategies with different tools, such as Google Ads and other digital fundraising platforms, to promote donations for the organization.
Keep the website updated and generate new content monthly
What are the organization's capabilities for doing this?
We have an excellent multidisciplinary team that is totally capable and willing to engage in the tasks that are necessary to achieve our goals. We are a young organization that is quickly growing, and as we believe in teamwork we attempt to increase our alliances worldwide. No big goal can be achieved by only one organization, and this is why our networking efforts are part of our daily work. In this sense, we now have the important support of a few companies and individuals that help us succeed in our work. Today we have 4 signed agreement of collaborators for the area of clinical trials and technology. In addition, since the inception 23 interns have been trained in different areas of the organization such as: communications, design, language and healthcare.
What have they accomplished so far and what's next?
Achievements
Cancer Immunotherapy
ConvitVax in clinical trials
As part of JCWO’s objectives, an important effort was made with the support of the ad-honorem specialist team to significantly improve the clinical protocol to the highest standards in accordance to the standards of the National Cancer Institute. The first trial is expected to begin in Venezuela, as soon as their top regulatory authority, Instituto Nacional de Higiene Rafael Rangel, gives their final approval. The first review has already been carried out and the corrections were delivered to the regulatory authority.
ConvitVax in pre-clinical studies
To continue the pre-clinical studies of the vaccine, a new study was designed in which ConvitVax is combined with CTLA-4. This design was reviewed and corrected by the team of researchers and Scientific Advisor. The experiment is expected to begin this year at FJC’s facilities with the support of JCWO.
Agreements
The Danish BCG vaccine producer of strain 1331, AJ Vaccines A/S, reviewed and approved JCWO’s clinical protocol -already authorized by the FDA- to conduct a phase I trial in 40 metastatic breast cancer patients, using ConvitVax with their BCG vaccine, for which they will guarantee the product supply. Additionally, AJ Vaccine A / S will supply the PPD test for monitoring the immune response of patients as established in the clinical protocol. JCWO has already signed an agreement in which it undertakes to notify any side effects generated by the PPD and currently the agreement between the two organizations is under review by the company's legal department.
Publications
In September 2020, after several years of recovering and compiling information on the life and work of Doctor Jacinto Convit, we were pleased and proud to publish in a peer-reviewed journal the biography titled " Biografía Doctor Jacinto Convit: Médico, científico, docente y humanista" in Gaceta Medica de Caracas (Huerta, et al. 2020). This publication represents the first and most complete official biography of Dr. Jacinto Convit.
The vaccine toxicity work entitled "Toxicity Evaluation of the ConvitVax - an autologous breast cancer vaccine - in a murine model" was submitted for review by the indexed journal Scientific Report. Currently, the organization is correcting the observations made by the reviewers and the inclusion of pathological data from the main organs evaluated.
Funding for JCWO’s programs
This year the fundraising area was strongly boosted. During 2020 we sent aproximately 394 letters to request funds (companies, institutions, banks), and 118 grant applications. Until now, we have received rejections from 69 applications; however, others 49 are pending for resolution. Additionally, due to the pandemic, resources and donations have been directed mainly to face this problem. Next year's intensive search for funding and new strategies will continue in order to find the necessary resources for our programs and to cover operational costs.
Financials
Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more
about GuideStar Pro.
Operations
The people, governance practices, and partners that make the organization tick.
Connect with nonprofit leaders
SubscribeBuild relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.
Connect with nonprofit leaders
SubscribeBuild relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.
Jacinto Convit World Organization, Inc.
Board of directorsas of 01/29/2024
Dr. Antonio Convit
Jacinto Convit World Organization Inc.
Term: 2020 -
Antonio Convit
NYU School of Medicine
Rafael Convit
Medstar National Rehabilitation Hospital
Lilia Correa
Indian River Medical Center
Mauricio Aranguren
UBS AG Wealth Management Americas
Ana Federica Convit
Jacinto Convit World Organization Inc.
Board leadership practices
GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.
-
Board orientation and education
Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? Yes -
CEO oversight
Has the board conducted a formal, written assessment of the chief executive within the past year ? No -
Ethics and transparency
Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? Yes -
Board composition
Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? Yes -
Board performance
Has the board conducted a formal, written self-assessment of its performance within the past three years? Yes
Organizational demographics
Who works and leads organizations that serve our diverse communities? Candid partnered with CHANGE Philanthropy on this demographic section.
Leadership
The organization's leader identifies as:
Race & ethnicity
Gender identity
Transgender Identity
Sexual orientation
No data
Disability
No data